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We evaluated the aspartate transaminase/alanine transaminase (De Ritis) ratio 
as a predictive biomarker for metastatic renal cell carcinoma patients undergoing 
cytoreductive nephrectomy, using propensity score matching. The ratio was an 
independent predictor for cancer-specific and overall survival after cytoreductive 
nephrectomy. This novel biomarker can be used to predict the prognosis of 
metastatic renal cell carcinoma patients before cytoreductive nephrectomy. 
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Abstract 
Background: The effect of the aspartate transaminase (AST)/alanine 
transaminase (ALT) ratio (De Ritis ratio) as a predictive biomarker for patients 
with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive 
nephrectomy (CN) remains unclear. 
Patients and Methods: One hundred and eighteen patients were retrospectively 
evaluated. Endpoints were set as cancer-specific survival (CSS) and overall 
survival (OS) after CN, and compared according to the AST/ALT ratio before and 
after 1:1 propensity score matching. The independent predictors for CSS and OS 
were also analyzed.  
Results: A result of the receiver operating characteristic curve showed that the 
area under the curve was 0.603. The maximum Youden index indicated that the 
cut-off value for the AST/ALT ratio was 1.24. Before matching, a high AST/ALT 
ratio was significantly associated with inferior CSS and OS (all p <0.05). After 
matching, 34 patients each were allocated to the high and low AST/ALT ratio 
groups. In the matched cohort, CSS and OS tended to be lower in patients in the 
high AST/ALT ratio group, although the results were not significant (median CSS: 
18.4 months vs. not reached, p = 0.121; OS: 18.4 months vs. not reached, p = 
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0.0957). Furthermore, multivariate analyses revealed that the AST/ALT ratio was 
an independent predictor for CSS and OS (CSS: hazard ratio [HR] 2.17, p = 
0.0472; OS: HR 2.30, p = 0.0258).   
Conclusion: The preoperative AST/ALT ratio can be an effective predictive 
biomarker for CSS and OS. 
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Introduction 
 Nearly one of five patients have a distinct metastasis at the time that renal cell 
carcinoma (RCC) is diagnosed 1. The prognosis of patients with metastatic RCC 
(mRCC) was poorer than that of others with stage I to III RCC; the 5-year relative 
survival in patients with stage IV did not reach 10% in a prior targeted therapy era 
1. Therefore, numerous studies have been performed to seek a proper and 
effective treatment strategy for mRCC, and to categorize patients into several 
prognostic models such as the Memorial Sloan-Kettering Cancer Center 
(MSKCC) risk classification 2. Cytoreductive nephrectomy (CN) has been 
identified as effective treatment for mRCC according to previous studies in the 
cytokine therapy era 3, 4 as well as those in the targeted therapy era 5, 6.  
Aminotransaminase, including the aspartate transaminase (AST) and alanine 
transaminase ratio (ALT), are enzymes released from liver cells into the blood 
stream, causing hepatocellular damage; thus, these are recognized as a part of 
the commonly requested panel for assessing liver function 7. The AST/ALT ratio 
(De Ritis ratio) has been identified as an independent predictor of patient survival 
from chronic hepatic disease 8 and solid organ malignancies 9-11. Moreover, two 
recent studies have reported that the preoperative AST/ALT ratio was significantly 
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associated with postoperative survival with localized RCC 12, 13. However, the 
effect of the AST/ALT ratio on survival after CN for mRCC remains unclear. Thus, 
we evaluated the effect of the preoperative AST/ALT ratio as a predictive 
biomarker of survival in patients with mRCC after CN. Moreover, to minimize 
selection bias, we adjusted patient variables using 1:1 propensity score matching. 
 
Patients and Methods 
This retrospective analysis included 140 consecutive patients with mRCC 
undergoing CN at our department between January 2003 and December 2015. 
Among them, patients who underwent hemodialysis (n = 16) and those whose 
clinicopathological data were missing (n = 6), were excluded from this analysis. 
The remaining 118 patients were enrolled. The endpoint was patient survival, 
including cancer-specific survival (CSS) and overall survival (OS) after CN. 
Predictors for CSS and OS were evaluated according to several perioperative 
clinicopathological parameters, including the preoperative AST/ALT ratio. A blood 
sample was obtained within 1 week preoperatively. All patients underwent 
imaging examinations, including computed tomography of the chest, abdomen 
and pelvis within 2 months preoperatively. The tumors were classified according 
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to the 2009 Union for International Cancer Control/American Joint Committee on 
Cancer consensus and the World Health Organization (2004) classification 
systems. Cellular grading was performed using the Fuhrman grading system 14. 
The CSS and OS were determined at the last follow-up using the date of surgery 
to the date of cancer-specific mortality and any cause mortality, respectively. To 
minimize selection bias between patients with a high AST/ALT ratio and those 
with a low AST/ALT ratio, patients’ variables were adjusted using 1:1 propensity 
score matching.  
Clinicopathological and laboratory data were extracted from an electronic 
database and patients’ medical records. The Internal Ethics Review Board of 
Tokyo Women’s Medical University approved this retrospective study (ID: 4109), 
which was performed in accordance with the principles outlined in the Declaration 
of Helsinki.  
 
Statistical analysis 
All analyses were performed using JMP software (version 11; SAS Institute Inc., 
Cary, NC, USA). Propensity scores were calculated using multivariable logistic 
regression. Continuous variables were analyzed using the Mann-Whitney U-test, 
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and categorical variables were analyzed using the χ2 test. The CSS and OS were 
calculated using the Kaplan-Meier method, and statistical significance was 
determined using the log-rank test. The efficacy of using the AST/ALT ratio to 
predict CSS was analyzed using the receiver operating characteristic (ROC) 
curve and the area under curve (AUC). The cut-off value for this marker was also 
defined using the maximum Youden index 15. Univariate and multivariate 
analyses were used to identify factors associated with CSS and OS using Cox 
proportional hazards regression models. The risk of survival is expressed as 
hazard ratios (HRs) and 95% confidence intervals (CIs), and differences were 
considered statistically significant at p-values < 0.05. 
 
Results  
Patients’ characteristics  
According to the maximum Youden index value, the cut-off value for the 
AST/ALT ratio was set at 1.24; therefore, patients with an AST/ALT ratio ≥ 1.24 
were classified into the high AST/ALT group, whereas the remaining patients (i.e., 
those with an AST/ALT ratio < 1.24) were classified into the low AST/ALT group.  
Of the 118 patients, 52 (44.1%) had a high AST/ALT ratio. Patient characteristics 
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before and after propensity score matching are summarized in Table 1. We were 
able to match 68 patients (34 patients in each group) (Figure 1). Before matching, 
the high AST/ALT group contained significantly more women (p < 0.001), and 
tended to be associated with older age, higher grades of pT and pN factors, and 
higher MSKCC risk. After matching, these differences between the two groups 
were acceptable.  
 
ROC curve of the AST/ALT ratio 
ROC analysis was generated for CSS, and the AUC value was statistically 
evaluated the discrimination ability of the AST/ALT ratio. The AUC of the AST/ALT 
ratio was 0.602 (95%CI 0.492 – 0.700), as shown in Figure 2. 
 
Survival according to AST/ALT ratio in cohorts before and after propensity score 
matching 
 Figures 3a and 3b show that CSS and OS were significantly lower in patients 
with a high AST/ALT ratio than in those with a low AST/ALT ratio before propensity 
score matching (median CSS: 18.4 months vs. not reached, p = 0.0116; OS: 17.5 
months vs. 81.5 months, p = 0.0040). After matching, Figures 4a and 4b show 
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that CSS and OS tended to be lower in patients with a high AST/ALT ratio; 
however, results were not significant (median CSS: 18.4 months vs. not reached, 
p = 0.121; OS: 18.4 months vs. not reached, p = 0.0957). 
 
Results of univariate and multivariate analyses for CSS and OS in cohorts before 
and after propensity score matching 
 Before matching, results of univariate analyses for CSS and OS showed that 
sex, the MSKCC risk classification, AST/ALT ratio, and CRP level were significant 
predictors (all, p < 0.05). Other parameters, including age, the number of 
metastatic lesions, presence of liver metastasis, surgical approach, pathology, 
nuclear grade, pT and pN factors, or presence of adjuvant systematic therapy 
were not statistically significant (all, p > 0.05). Results of multivariate analysis for 
CSS showed that the AST/ALT ratio was an independent predictor (HR 2.15 p = 
0.0119), together with the CRP level (HR 2.48 p = 0.0042) and MSKCC risk 
classification (HR 2.05 p = 0.0279). Results of multivariate analysis for OS 
showed that the AST/ALT ratio was an independent predictor (HR 2.26 p = 
0.0047), together with the MSKCC risk classification (HR 2.25 p = 0.0096) and 
CRP level (HR 2.05 p = 0.0153) (Table 2). 
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 After matching, on univariate analyses for CSS and OS, there was no significant 
difference in AST/ALT ratio (both p > 0.05). However, multivariate analyses for 
CSS and OS revealed that the AST/ALT ratio was an independent predictive 
factor (CSS: HR 2.17, p =0.0472; OS: HR 2.30, p =0.0258), after adjustment for 
possible factors including MSKCC risk classification and CRP level (Table 3).  
 
Discussion  
The present study showed that the preoperative AST/ALT ratio (De Ritis ratio) 
was an independent predictive biomarker for CSS and OS in patients with mRCC 
after CN. In a matched cohort, the Kaplan-Meier survival curve showed that the 
AST/ALT ratios were not significant; this result may have been due to the small 
sample size after propensity score matching. Indeed, on final multivariate 
analyses, after adjusting for other well-established predictors, including the 
MSKCC risk classification and CRP level 2, 16-19, the AST/ALT ratio was significant; 
therefore, we believe that the AST/ALT ratio could possibly be used to predict 
patient outcomes after CN for mRCC.  
The AST and ALT levels are effective predictive markers used to determine 
hepatic function, and to identify hepatic disease such as viral hepatitis and alcohol 
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abuse. AST is commonly produced in several organs such as the liver, heart, 
skeletal muscle, kidney, and brain, whereas ALT is specifically found in the liver 
8. Importantly, these aminotransaminases are also expressed in different cellular 
subcomponents by cancerous cells. The significant association between the 
AST/ALT ratio and various malignancies such as lung cancer 10, pancreatic 
cancer 11, and cholangiocarcinoma 9, has been indicated. In this context, Bezan 
et al. 12 first reported the AST/ALT ratio as an independent predictive biomarker 
for patients’ survival, including metastasis-free survival and OS, after curative 
nephrectomy for non-metastatic RCC. They also stated that this effective 
predictor might improve the predictive accuracy of a well-established prognostic 
model, as demonstrated in a cohort of 698 patients with non-metastatic RCC. 
Thereafter, Lee et al. 13 indicated that an increased AST/ALT ratio was 
significantly associated with worse postoperative survival, including progression-
free survival, CSS and OS, in patients surgically treated for localized clear-cell 
RCC in a cohort of 2965 patients in a propensity score-matched study. Although 
these two previous studies demonstrated the efficacy of the AST/ALT ratio as a 
useful biomarker for survival after curative nephrectomy for localized RCC, it 
remains unclear whether this novel marker can be effective in a population with 
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mRCC. To the best of our knowledge, this is the first study to indicate that the 
preoperative AST/ALT ratio has a potentially prognostic value for CSS and OS in 
patients with mRCC after CN.   
Although the mechanism of how the AST/ALT ratio predicts survival in patients 
with RCC remains unclear, previous studies have referenced the Warburg’s effect, 
which was the study of biochemical markers in neoplasms in regard to Warburg’s 
theory that cancer tissue showed a greater rate of aerobic glycolysis than normal 
tissue 20. For example, Lee et al. 13 hypothesized that von-Hippel-Lindau (VHL) 
loss, which was a key trigger of clear-cell RCC, induced hypoxia-induced factor 
expression, which had a relationship with extensively increased glycolysis 21. 
Moreover, AST has a vital role in glycolysis through the malate-aspartate shuttle 
pathway 22. Thus, they speculated that the AST and ALT levels may be involved 
in the glycolysis mechanism in clear-cell RCC with VHL loss. According to their 
hypothesis, as patients with mRCC are expected to have more cancer cells (i.e., 
they may have a much greater rate of aerobic glycolysis), there may be a stronger 
association with the AST/ALT ratio in the glycolysis mechanism, as shown in our 
results.    
Interestingly and importantly, we confirmed that the significant effect of the 
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AST/ALT ratio together with the CRP level. The CRP level is an independent 
predictive biomarker in patients with RCC with or without metastasis 16-19, 23, 24. 
The strong association between the CRP level and patient’s prognosis has been 
explained by previous experimental studies; CRP is produced in the liver and is 
strongly induced by interleukin-6 (IL-6). RCC cells can produce IL-6, and IL-6 
itself is recognized as a growth promoter in RCC cells 25, 26. Indeed, the CRP level 
was an independent predictor for CSS and OS in the present study. This result 
may represent different aspects of the mechanism of mRCC with regard to the 
prediction of prognosis; the CRP level may represent a systematic inflammatory 
response, whereas the AST/ALT ratio may represent a metabolic response under 
RCC cell condition. Indeed, there was no significant association between the 
AST/ALT ratio and CRP level (Table 1).  
 There were several limitations to this study. This was a retrospective study, 
performed at a single center with a small cohort; these factors may have 
introduced inherent selection bias of patients or treatments. Thus, patient 
backgrounds were matched between the high and low AST/ALT groups using 
propensity scoring, resulting in groups that were as well adjusted for analyses as 
possible. However, our findings should be confirmed in a prospective, multi-
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institution study with a large cohort. Moreover, because this was a retrospective 
study, we could not completely exclude the potential influence of undetected 
hepatic disorder (e.g., fatty liver or chronic liver disease) on AST and ALT levels. 
 
Conclusion 
The present study’s findings indicated that the preoperative AST/ALT ratio was 
an independent predictive biomarker for CSS and OS in patients with mRCC who 
underwent CN. The AST and ALT levels can be easily evaluated and monitored 
in routine clinical practice without invasive procedures. This novel biomarker can 
help predict prognosis in patients with mRCC before CN.   
 
Clinical practice points 
 Recent studies have reported that the preoperative aspartate transaminase 
(AST)/alanine transaminase (ALT) ratio (De Ritis ratio) was significantly 
associated with postoperative survival with localized renal cell carcinoma. 
 The effect of the AST/ALT ratio on survival after cytoreductive nephrectomy 
for metastatic renal cell carcinoma remains unclear. 
 We demonstrated that preoperative AST/ALT ratio was an independent 
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predictive biomarker for cancer-specific and overall survival after 
cytoreductive nephrectomy in a propensity score-matched cohort.  
 The AST/ALT ratio can help predict prognosis in patients with metastatic renal 
cell carcinoma before cytoreductive nephrectomy.   
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Figure legends 
Figure 1: Study design  
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AST, aspartate transaminase; ALT, alanine transaminase 
 
Figure 2: Receiver operating characteristic analysis of AST/ALT ratio  
Receiver operating characteristic analysis for cancer-specific survival included 
118 patients. The AUC of the preoperative AST/ALT ratio was 0.602.  
AUC, area under the curve; AST, aspartate transaminase; ALT, alanine 
transaminase  
 
Figure 3: Cancer-specific and overall survivals after cytoreductive nephrectomy 
according to the preoperative AST/ALT ratio before propensity score matching  
The survival rate was calculated using the Kaplan-Meier method and compared 
using the log-rank test.  
AST, aspartate transaminase; ALT, alanine transaminase 
 
Figure 4: Cancer-specific and overall survivals after cytoreductive nephrectomy 
according to the preoperative AST/ALT ratio after propensity score matching  
The survival rate was calculated using the Kaplan-Meier method and compared 
using the log-rank test.  
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Table 1: Patients demographics and clinical characteristics before and after propensity score matching  
 Before matching After matching 
Parameters  Low  
AST/ALT (n = 66) 
High  
AST/ALT (n = 52) 
p Low  
AST/ALT (n = 34) 
High  
AST/ALT (n = 34) 
p 
Age, years 
 ≥ 65 (vs. < 65) 
 
28 (42.4%) 
 
28 (53.9%) 
0.217  
16 (47.1%) 
 
19 (55.9%) 
0.466 
Sex 
 Female (vs. male) 
 
9 (13.6%) 
 
24 (46.2%) 
<0.0001  
7 (20.6%) 
 
7 (20.6%) 
1.000 
Number of metastatic lesions 
 Multiple (vs. solitary) 
 
17 (25.8%) 
 
13 (25.0%) 
0.925  
9 (26.5%) 
 
8 (23.5%) 
0.779 
Liver metastasis 
 With (vs. without) 
 
5 (7.58%) 
 
4 (7.69%) 
0.981  
3 (8.82%) 
 
3 (8.82%) 
1.000 
Surgical approach  
 Open (vs. laparoscopy) 
 
57 (86.4%) 
 
42 (80.8%) 
0.412  
28 (82.4%) 
 
26 (76.5%) 
0.549 
Pathology  
 CCC (vs. non-CCC) 
 
59 (89.4%) 
 
46 (88.5%) 
0.872  
27 (79.4%) 
 
30 (88.2%) 
0.323 
Nuclear grade 
 3 (vs. 1 and 2) 
 
39 (59.1%) 
 
33 (63.5%) 
0.629  
20 (58.8%) 
 
21 (61.8%) 
0.804 
pT factor 
 ≥ 3 (vs. < 3) 
 
47 (71.2%) 
 
43 (82.7%) 
0.146  
28 (82.4%) 
 
28 (82.4%) 
1.000 
pN factor 
 ≥ 1 (vs. 0 and X) 
 
14 (21.2%) 
 
18 (34.6%) 
0.104  
23 (67.6%) 
 
23 (67.6%) 
1.000 
MSKCC risk 
 Poor (vs. intermediate) 
 
10 (15.2%) 
 
14 (26.9%) 
0.115  
26 (76.5%) 
 
26 (76.5%) 
1.000 
2 
 
Systematic therapy 
 Without (vs. with) 
 
11 (52.4%) 
 
10 (47.6%) 
0.718  
9 (26.5%) 
 
9 (26.5%) 
1.000 
CRP level, mg/ dl 
 ≥ 1.0 (vs. < 1.0) 
 
41 (57.8%) 
 
30 (42.3%) 
0.626  
18 (52.9%) 
 
20 (58.8%) 
0.625 
*Follow-up period, months 25.9 ± 26.8 20.5 ± 25.3 0.274 21.0 ± 24.3 23.0 ± 28.8 0.751 
 
*Mean ± standard deviation 
AST, aspartate transaminase; ALT, alanine transaminase; CCC, clear-cell carcinoma; MSKCC, Memorial Sloan-Kettering 
Cancer Center; CRP, C-reactive protein; ref., reference 
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Table 2: Results of univariate and multivariate analyses for cancer-specific and overall survivals before propensity score 
matching  
Parameters CSS 
Univariate  
HR (95% CI) 
p CSS 
Multivariate  
HR (95% CI) 
p OS 
Univariate  
HR (95% CI) 
p OS 
Multivariate  
HR (95% CI) 
p 
Age, years 
 ≥ 65 (vs. < 65) 
0.94 (0.54 – 1.61) 0.815 
  
1.09 (0.65 – 1.83) 0.742 
  
Sex 
 Female (vs. male) 
1.90 (1.05 – 3.33) 0.0339 1.18 (0.62 – 2.18) 0.611 1.79 (1.01 – 3.06) 0.0466 1.08 (0.58 – 1.95) 0.794 
Number of metastatic lesions 
 Multiple (vs. solitary) 
1.74 (0.92 – 3.13) 0.0873 
  
1.82 (1.00 – 3.18) 0.0514 
  
Liver metastasis 
 With (vs. without) 
1.88 (0.56 – 4.66) 0.268 
  
2.14 (0.74 – 4.90) 0.145 
  
Surgical approach 
 Open (vs. laparoscopy) 
1.26 (0.61 – 3.06) 0.558 
  
1.20 (0.60 – 2.74) 0.627 
  
Pathology  
 CCC (vs. non-CCC) 
0.55 (0.25 – 1.47) 0.216 
  
0.62 (0.28 – 1.63) 0.302 
  
Nuclear grade 
 3 (vs. 1 and 2) 
1.31 (0.76 – 2.31) 0.333 
  
1.22 (0.72 – 2.08) 0.460 
  
pT factor 
 ≥ 3 (vs. < 3) 
1.06 (0.59 – 1.99) 0.850 
  
1.25 (0.71 – 2.32) 0.459 
  
pN factor 
 ≥ 1 (vs. 0 and X) 
1.29 (0.66 – 2.36) 0.440 
  
1.35 (0.72 – 2.38) 0.333 
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MSKCC 
 Poor (vs. intermediate) 
2.85 (1.55 – 5.04) 0.0011 2.05 (1.08 – 3.76) 0.0279 2.94 (1.65 – 5.06) 0.0004 2.25 (1.23 – 4.01) 0.009
6 
Systematic therapy 
 With (vs. without) 
1.02 (0.49 – 2.48) 0.960 
  
0.98 (0.49 – 2.23) 0.948 
  
AST/ALT ratio 
 ≥ 1.24 (vs. < 1.24) 
1.99 (1.16 – 3.46) 0.0128 2.15 (1.18 – 3.92) 0.0119 2.10 (1.26 – 3.57) 0.0046 2.26 (1.28 – 4.00) 0.004
7 
CRP, mg/dl 
 ≥ 1.0 (vs. < 1.0) 
2.54 (1.41 – 4.86) 0.0016 2.48 (1.32 – 4.88) 0.0042 2.12 (1.23 – 3.79) 0.0064 2.05 (1.15 – 3.80) 0.015
3 
CSS, cancer-specific survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; CCC, clear-cell carcinoma; 
MSKCC, Memorial Sloan-Kettering Cancer Center; AST, aspartate transaminase; ALT, alanine transaminase; CRP, C-reactive 
protein 
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Table 3: Results of univariate and multivariate analyses for cancer-specific and overall survivals after propensity score 
matching  
Parameters CSS 
Univariate  
HR (95% CI) 
p CSS 
Multivariate  
HR (95% CI) 
p OS 
Univariate  
HR (95% CI) 
p OS 
Multivariate  
HR (95% CI) 
p 
Age, years 
 ≥ 65 (vs. < 65) 
0.69 (0.33 – 1.43) 0.319 
  
0.83 (0.41 – 1.66) 0.588 
  
Sex 
 Female (vs. male) 
1.55 (0.61 – 3.45) 0.331 
  
1.38 (0.55 – 3.03) 0.462 
  
Number of metastatic lesions 
 Multiple (vs. solitary) 
1.83 (0.78 – 3.98) 0.155 
  
1.92 (0.86 – 4.02) 0.109 
  
Liver metastasis 
 With (vs. without) 
1.60 (0.38 – 4.59) 0.471 
  
1.44 (0.34 - 4.08) 0.572 
  
Surgical approach 
 Open (vs. laparoscopy) 
1.22 (0.53 – 3.31) 0.661 
  
1.14 (0.52 – 2.85) 0.764 
  
Pathology  
 CCC (vs. non-CCC) 
0.84 (0.31 – 2.91) 0.755 
  
0.89 (0.33 – 3.07) 0.830 
  
Nuclear grade 
 3 (vs. 1 and 2) 
0.90 (0.44 – 1.88) 0.778 
  
0.84 (0.42 – 1.70) 0.630 
  
pT factor 
 ≥ 3 (vs. < 3) 
1.20 (0.52 – 3.27) 0.682 
  
1.32 (0.58 – 3.57) 0.527 
  
pN factor 
 ≥ 1 (vs. 0 and X) 
0.74 (0.27 – 1.70) 0.494 
  
0.80 (0.32 – 1.77) 0.600 
  
6 
 
MSKCC 
 Poor (vs. intermediate) 
1.99 (0.89 – 4.18) 0.0904 1.62 (0.68 – 3.66) 0.268 2.31 (1.10 – 4.65) 0.0283 1.95 (0.87 – 4.23) 0.104 
Systematic therapy 
 With (vs. without) 
0.70 (0.31 – 1.92) 0.469 
  
0.67 (0.31 – 1.69) 0.373 
  
AST/ALT ratio 
 ≥ 1.24 (vs. < 1.24) 
1.81 (0.86 – 4.03) 0.117 2.17 (1.01 – 4.98) 0.0472 1.83 (0.91 – 3.93) 0.0921 2.30 (1.10 – 5.08) 0.0258 
CRP, mg/dl 
 ≥ 1.0 (vs. < 1.0) 
2.66 (1.27 – 5.98) 0.0095 2.46 (1.10 – 5.79) 0.0280 2.64 (1.30 – 5.70) 0.0070 2.31 (1.06 – 5.23) 0.0340 




